Qianjin Pharmaceutical announced that the company and its subsidiary Qianjin Xiangjiang Pharmaceutical recently received “Drug Registration Certificates” for didroprogesterone tablets, baritinib tablets, and dapagliflozin tablets approved and issued by the State Drug Administration. The approval of these drugs will further enrich the company's product pipeline, which is conducive to sustainable development. However, it is important to note that drug production and sales are affected by factors such as policies and market environments, and there is uncertainty.

Qianjin Pharmaceutical announced that the company and its subsidiary Qianjin Xiangjiang Pharmaceutical recently received “Drug Registration Certificates” for didroprogesterone tablets, baritinib tablets, and dapagliflozin tablets approved and issued by the State Drug Administration. The approval of these drugs will further enrich the company's product pipeline, which is conducive to sustainable development. However, it is important to note that drug production and sales are affected by factors such as policies and market environments, and there is uncertainty.